Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTRENIM – Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia
2015-005248-33Phase 3Active
- Sponsor
- GIMEMA
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nilotinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by GIMEMA. Primary endpoint: MR4.5 rate at 24 months. Started Apr 2018; status: active.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2015-005248-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005248-33.